Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Provided By PR Newswire
Last update: Jul 25, 2025
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Read more at prnewswire.com734.17
-1.86 (-0.25%)
Find more stocks in the Stock Screener
LLY Latest News and Analysis
